Gwenn Hansen

Company: Nurix Therapeutics

Job title: Chief Scientific Officer

Seminars:

Panel Discussion: DACs, Protacs & Molecular Glues: Why is ADC Technology What Protein Degradation Needs? 8:15 am

Discussing mechanistic differences across protein degradation payloads, their therapeutic role, and liabilities Demonstrating a protein degradation therapeutic window, and selective delivery with antibodies Understanding why protein degradation experts believe ADC technology is neededRead more

day: Day Two -AM

Tumor-Specific Delivery of Potent Degraders 10:00 am

Introducing Nurix’ expertise in DELigase, targeted protein modulation, targeted protein degradation, targeted protein elevation, and degrader-antibody conjugates Targeting degraders to the CNS for the treatment of cancer Discussing collaborationsRead more

day: Day Two -AM